Literature DB >> 22071972

Effect of topical interferon-γ gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in Tsk/+ mice.

I Badea1, C Virtanen, R E Verrall, A Rosenberg, M Foldvari.   

Abstract

Scleroderma is a chronic disorder manifested by excessive synthesis and deposition of collagen in skin and connective tissue, vascular abnormalities, and autoimmunity. Using microarray and real-time PCR data, we show that intradermally expressed interferon γ (IFN-γ), generated after intradermal injection of IFN-γ-coding plasmid, and non-invasive topical nanoparticle (TNP) treatment with IFN-γ-coding plasmid, decreased collagen synthesis (via the Jak/Stat 1 pathway), upregulated Th1 cytokine levels, and downregulated the profibrotic cytokine Transforming growth factor β and the Smad pathways in the Tsk/+ (tight-skin scleroderma) mouse model. The TNP gene delivery system was constructed from gemini surfactant 16-3-16 and IFN-γ-coding plasmid. Topical administration of IFN-γ-coding plasmid in TNPs was effective in expressing IFN-γ levels after a 20-day treatment regimen without increased TLR4, CCL2, CCL11 and CCR2 mRNA levels that were observed in injected animals, signs considered to be innate responses to injury. The more uniform transgene IFN-γ expression caused significant (70-72%) collagen reduction, as assessed by reverse transcription real-time PCR. These results demonstrate efficient in vivo transfection using a gemini surfactant-based TNP delivery system able to modulate excessive collagen synthesis in scleroderma-affected skin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071972     DOI: 10.1038/gt.2011.159

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism.

Authors:  Pavel Kopach; Virginia Lockatell; Edward M Pickering; Ronald E Haskell; Richard D Anderson; Jeffrey D Hasday; Nevins W Todd; Irina G Luzina; Sergei P Atamas
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

2.  Cyclodextrins in drug delivery: applications in gene and combination therapy.

Authors:  Rebecca M Haley; Riccardo Gottardi; Robert Langer; Michael J Mitchell
Journal:  Drug Deliv Transl Res       Date:  2020-06       Impact factor: 4.617

3.  Impact of phospholipids on plasmid packaging and toxicity of gemini nanoparticles.

Authors:  Chilbert Dong; Ildiko Badea; Masoomeh Poorghorban; Ronald Verrall; Marianna Foldvari
Journal:  J Mater Chem B       Date:  2015-09-29       Impact factor: 6.331

4.  Design and Evaluation of RGD-Modified Gemini Surfactant-Based Lipoplexes for Targeted Gene Therapy in Melanoma Model.

Authors:  Waleed Mohammed-Saeid; Jackson Chitanda; Mays Al-Dulaymi; Ronald Verrall; Ildiko Badea
Journal:  Pharm Res       Date:  2017-06-22       Impact factor: 4.200

5.  Cellular Uptake and Distribution of Gemini Surfactant Nanoparticles Used as Gene Delivery Agents.

Authors:  Wei Jin; Mays Al-Dulaymi; Ildiko Badea; Scot C Leary; Jeveria Rehman; Anas El-Aneed
Journal:  AAPS J       Date:  2019-08-06       Impact factor: 4.009

Review 6.  Animal models of systemic sclerosis: their utility and limitations.

Authors:  Carol M Artlett
Journal:  Open Access Rheumatol       Date:  2014-07-01

Review 7.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.

Authors:  Flávia Castro; Ana Patrícia Cardoso; Raquel Madeira Gonçalves; Karine Serre; Maria José Oliveira
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

Review 8.  Microvascular targets for anti-fibrotic therapeutics.

Authors:  Kai-Ming T Pu; Parid Sava; Anjelica L Gonzalez
Journal:  Yale J Biol Med       Date:  2013-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.